Important OptumRx updates to support providers, clinical staff and patients through COVID-19.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 23, 2019 - The FDA approved Exeltis’ Slynd (drospirenone), for use by females of reproductive potential to prevent pregnancy.
Download PDF
Return to publications
